The metal complexes of amine-carboxyborane including copper, chromium, zinc, calcium amd cobalt were effective hypolipidemic agents lowering both serum cholesterol and triglyceride levels significantly in mice at 8 mg/kg/day, I.P. after 16 days. The agents reduced acetyl CoA synthetase, ATP-dependent citrate lyase, acyl CoA cholesterol acyl transferase, sn-glycerol-3-phosphate acyl transferase activities of rat liver and small intestinal mucosa after 14 days treatment. The neutral cholesterol ester hydrolase activity was elevated by the agents in both tissues. The metal complexes altered lipid levels in the bile of rats after treatment as well as the bile acid composition after 14 days administration, orally. The agents blocked enterohepatic absorption of cholesterol from rat isolated intestinal loops.
INTRODUCTION
Amine-carboxyboranes have proven to be effective hypolipidemic agents in mice I.P. and rats, orally at 5-20 mg/kg/day [1] [2] [3] [4] . Both serum cholesterol and triglyceride levels are significantly reduced. These agents successfully reduced VLDL and LDL cholesterol levels and elevated HDL cholesterol levels in rats. One of the modes of action of the derivatives was the suppression of rate limiting enzyme activities of de novo synthesis of lipids. One particular derivative tetrakis-u-(trimethylamine-boranecarboxylato)-bis(trimethylaminecarboxyborane)-dicopper (II), compound 1, demonstrated excellent activity at 2.5 mg/kg/day [5] . Preliminary studies suggested that this derivative increase lipid excretion in the bile of rats [5] . Thus, the present study extends the investigation of metal complexes of amine-carboxyboranes as hypolipidemic agents and their role on biliary lipid excretion in rodents.
MATERIALS AND METHODS

Source of Material and Compounds
The synthesis and physical characteristics of these complexes has previously been reported:
Cu(u-(CH3)3NBH2COO)4.2(CH3)3NBH2COOH 1 [6] [Fe30((CH3)3NBH2COO)6(CH3OH)]NO3.CH3CN 2 [7] , [Fe30((CH3)3NBH2COO)6(CH3OH)3]CI 3 [7] , [Cr30((CH3) 3 NBH2COO)6(H20)3]NO3.CH3OH.CH3CN 4 [7] , cis[Co(en)2 ((CH3)3NBH2COO)2]C1-2.5 H20.0.5 CH3OH , [8] , ZnC12.2 (CH3)3NBH2CN 6 [9] , Ca((CH3) 3 N.BH2COO) NO3.CH3 COCH3.0.5H20 7 [8] , Na(NH3.BH2CN)6I $ [10] , Na(CH3)3NBH2COO'0.25CH3OH 9 [7] , Na(CH3) 2 NBH 2 COO.0.45H20 10 [7] , Na(CH3)2NBH 3 11 [commercially available], NaBH3CN 12, Na2BH3COO 13, and Na2B10H10.H20
Test compounds were administered to CF-1 male mice (28g) at 8 mg/kg/day I.P, for 16 days. On days 9 and 16, blood was obtained by tail-vein bleeding and the serum was obtained by centrifugation at 3500 g x 10 min. The serum cholesterol levels were determined by a modification of the Liebermann-Burchard reaction [12] . Serum triglyceride were determined using a commercial kit [Boehringer Mannheim Diagnostics].
Sprague Dawley male rats (~280g) were administered compound 1 at 2.5 mg/kg/day, orally and compound 4 at 8 mg/kg/day orally. Blood was collected on day 14 for serum lipid analysis. These doses were selected based on a preliminary pilot study for the best efficacy of the indivivdual agents in rats.
Treatment of Rats
Bile Cannulation Studies. Sprague Dawley male rats (~300g) were administered compounds 1 at 2.5 mg/kg/day or 4 at 8 mg/kg/day by intubation tube, orally for 14 days. The rats were administered chlorpromazine (25mg/kg) and anesthetized 30 minutes later with pentobarbital (22 mg/kg i.p.) [13] , a combination which reduces the amount of pentobarbital necessary to maintain anesthesia level over extended periods of time without bronchial spasms. An incision was made just below the rib cage to expose the stomach and the duodenum. Once the bile duct was indentified, a loose ligature was placed around it and the duct was knicked. PE-10 plastic tubing was placed in the duct and tied in place. The bile was collected from the control and treated groups over the next 6 hours while the animals were maintained under anesthesia.
Bile Lipid Levels. The flow rate of the bile was calculated for each group as ml/min. Aliquots were extracted for lipids by the Folch et al. [14] and Bligh and Dyer [15] methods. Cholesterol [12] , triglyceride [BioDynamics/bmc trigtyceride kit], neutral lipids [16] , and phospholipid contents [17] were determined. Protein concentrations were also determined [18] .
HPLC Analysis of Bile Acids Content. Samples were frozen overnight and thawed. The bile lipids were extracted with EtOH:water; [1:20] and filtered [19, 20] . Aliquots (250 l.tl) of the bile were added to 10 l.tl of the internal standard (testosterone). Then 6* See Table 2 for standard values for control assays lipids were within normal limits. Compound 4 afforded a 60% increase in biliary cholesterol and a 77% increase in biliary phospholipid levels after 14 days. The bile salt concentrations were also altered after drug treatment, e.g. taurocholic, glycocholic, taurodeoxycholic, glycochenodeoxycholic and lithocholic acids were reduced by compound while tauroursodeoxycholic, and glycourodeoxycholic acids were elevated and taurochenodeoxycholic acid was not changed from the control value. Compounds 4 reduced the levels of taurocholic, taurodeoxycholic, and glycourodeoxycholic acids.
Taurochendeoxycholic, glycocholic and tauroursodeoxycholic acids were elevated after treatment. Both compounds retarded cholesterol absorption from isolated intestinal loops after 180 min [ Fig. and 3] . Only compound 4 blocked cholic acid absorption from the isolated loops after 180 min [ Fig. 2 and 4 ]. [34] . Thus, there is no reason to think that these hypolipidemic agents may cause the formation of gall stones. Changes in bile acids can cause choleresis for example in decreasing order dehydrocholic > chenodeoxycholic > cholic acid > taurocholic acid > deoxycholic > glycocholic acid [35] . Compound 1 resulted in increases in glycourodeoxycholic acid and tauroursodeoxycholic acid which may have influenced the increase in bile flow observed for this agent. Compound 4 demonstrated no such large increases in any of the bile acids and no increase in bile flow. Gall stone formation has been linked with high levels of hepatic HMG CoA reductase activity and low levels of cholesterol-7-a hydroxylase activity. Neither compound created elevated HMG CoA reductase activity but both caused reduced cholesterol-7-a hydroxylase activity. This latter enzyme is the regulatory enzyme for the conversion of cholesterol to bile acids and should affect the bile acid profile if reduced in activity.
One mode of action of the metal complexes of amine carboxyborane derivatives was to block the resorption of cholesterol from the intestine thus returning it to the liver via the portal vein. Blocking this process is a viable mode of action of hypolipidemic agents, colestipol and cholestyramine, and would be additive with the other mode of action of the derivatives of inhibiting regulatory enzyme activities of de novo synthesis of lipids in the liver and small intestinal mucosa. 
